Crain's New York8d
Midtown drug startup raises $13M to capitalize on opioid-alternative boom
The market for non-opioid painkillers is booming in the wake of a devastating overdose crisis and an opioid industry far ...
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...
Vertex's painkiller results match placebo in study, shares tumble
Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...
Vertex's $10 Billion Blow: Painkiller Trial Results Spark Investor Panic
They're pressing ahead with a Phase 3 trial, banking on tweaks to trial designs to tackle what they're calling a placebo ...
The Boston Globe9d
Vertex stock plummets as study results show non-opioid pain drug no better than placebo
Some analysts had said the painkiller might be a multibillion-dollar business for a company needing a next big driver of ...
Vertex wins approval for new once-daily CF drug
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
BioSpace5d
Vertex Wins FDA Approval for New Cystic Fibrosis Option but Stock Still Down
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...
SchaeffersResearch.com9d
Vertex Pharmaceuticals Stock Heads for Worst Day in 4 Years
Vertex Pharmaceuticals (VRTX) is plummeting after disappointing trial results, headed for its worst day in four years ...
Wall Street Journal9d
Vertex Stock Plunges Over Pain Drug’s Disappointing Study Results
Shares of Vertex Pharmaceuticals sank Thursday, following disappointing study results for a non-opioid painkiller. Vertex said the drug significantly reduced pain in people with a common form of lower ...